|
1
|
Chia VM, Quraishi SM, Devesa SS, Purdue
MP, Cook MB and McGlynn KA: International trends in the incidence
of testicular cancer, 1973–2002. Cancer Epidemiol Biomarkers Prev.
19:1151–1159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vasdev N, Moon A and Thorpe AC:
Classification, epidemiology and therapies for testicular germ cell
tumours. Int J Dev Biol. 57:133–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Purdue MP, Devesa SS, Sigurdson AJ and
McGlynn KA: International patterns and trends in testis cancer
incidence. Int J Cancer. 115:822–827. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ries LAG, Young JL Jr, Keel GE, Eisner MP,
Lin YD and Horner M-JD: SEER Survival Monograph: Cancer Survival
Among Adults: U.S. SEER Program, 1988–2001. Patient and Tumor
CharacteristicsNational Cancer Institute, SEER Program, NIH Pub.
No. 07-6215. Bethesda, MD: 2007
|
|
5
|
Hayes-Lattin B and Nichols CR: Testicular
cancer: A prototypic tumor of young adults. Semin Oncol.
36:432–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raghavan D: Testicular cancer: Maintaining
the high cure rate. Oncology (Williston Park). 17:218–229, 234-235.
2003.PubMed/NCBI
|
|
7
|
Li J, Quan H, Liu Q, Si Z, He Z and Qi H:
Alterations of axis inhibition protein 1 (AXIN1) in hepatitis B
virus-related hepatocellular carcinoma and overexpression of AXIN1
induces apoptosis in hepatocellular cancer cells. Oncol Res.
20:281–288. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Salahshor S and Woodgett JR: The links
between axin and carcinogenesis. J Clin Pathol. 58:225–236. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park JY, Park WS, Nam SW, Kim SY, Lee SH,
Yoo NJ, Lee JY and Park CK: Mutations of beta-catenin and AXIN I
genes are a late event in human hepatocellular carcinogenesis.
Liver Int. 25:70–76. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mazzoni SM and Fearon ER: AXIN1 and AXIN2
variants in gastrointestinal cancers. Cancer Lett. 355:1–8. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa
N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, et al:
AXIN1 mutations in hepatocellular carcinomas and growth suppression
in cancer cells by virus-mediated transfer of AXIN1. Nat Genet.
24:245–250. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kishida S, Yamamoto H, Ikeda S, Kishida M,
Sakamoto I, Koyama S and Kikuchi A: Axin, a negative regulator of
the wnt signaling pathway, directly interacts with adenomatous
polyposis coli and regulates the stabilization of beta-catenin. J
Biol Chem. 273:10823–10826. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deng F, Li S, Xu W, Zou Z, Ke Z and Zeng
F: AXIN1-related CSRNP1 mRNA expression and its transcriptional
regulation in TGF-beta1-induced tumor cells. Nan Fang Yi Ke Da Xue
Xue Bao. 33:1122–1126. 2013.(In Chinese). PubMed/NCBI
|
|
14
|
Zhang Y, Neo SY, Wang X, Han J and Lin SC:
Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal
kinase/stress-activated protein kinase through domains distinct
from Wnt signaling. J Biol Chem. 274:35247–35254. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W,
Zhou HM, Cheung PY, Wu Z, Ye Z, et al: Axin stimulates p53
functions by activation of HIPK2 kinase through multimeric complex
formation. EMBO J. 23:4583–4594. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fritsch MK, Schneider DT, Schuster AE,
Murdoch FE and Perlman EJ: Activation of Wnt/beta-catenin signaling
in distinct histologic subtypes of human germ cell tumors. Pediatr
Dev Pathol. 9:115–131. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dahmen RP, Koch A, Denkhaus D, Tonn JC,
Sörensen N, Berthold F, Behrens J, Birchmeier W, Wiestler OD and
Pietsch T: Deletions of AXIN1, a component of the WNT/wingless
pathway, in sporadic medulloblastomas. Cancer Res. 61:7039–7043.
2001.PubMed/NCBI
|
|
18
|
Ngalame NN, Tokar EJ, Person RJ and
Waalkes MP: Silencing KRAS overexpression in arsenic-transformed
prostate epithelial and stem cells partially mitigates malignant
phenotype. Toxicol Sci. 142:489–496. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Figeac N and Zammit PS: Coordinated action
of Axin1 and Axin2 suppresses β-catenin to regulate muscle stem
cell function. Cell Signal. 27:1652–1665. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek
TJ, Perry WL III, Lee JJ, Tilghman SM, Gumbiner BM and Costantini
F: The mouse Fused locus encodes Axin, an inhibitor of the Wnt
signaling pathway that regulates embryonic axis formation. Cell.
90:181–192. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de la Roche M, Ibrahim AE, Mieszczanek J
and Bienz M: LEF1 and B9L shield β-catenin from inactivation by
Axin, desensitizing colorectal cancer cells to tankyrase
inhibitors. Cancer Res. 74:1495–1505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu C, Li Y, Semenov M, Han C, Baeg GH,
Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell.
108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
L'Esperance S, Popa I, Bachvarova M,
Plante M, Patten N, Wu L, Têtu B and Bachvarov D: Gene expression
profiling of paired ovarian tumors obtained prior to and following
adjuvant chemotherapy: Molecular signatures of chemoresistant
tumors. Int J Oncol. 29:5–24. 2006.PubMed/NCBI
|
|
25
|
Rada P, Rojo AI, Offergeld A, Feng GJ,
Velasco-Martín JP, González-Sancho JM, Valverde ÁM, Dale T,
Regadera J and Cuadrado A: WNT-3A regulates an Axin1/NRF2 complex
that regulates antioxidant metabolism in hepatocytes. Antioxid
Redox Signal. 22:555–571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cavazzoni A, Bonelli MA, Fumarola C, La
Monica S, Airoud K, Bertoni R, Alfieri RR, Galetti M, Tramonti S,
Galvani E, et al: Overcoming acquired resistance to letrozole by
targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Cancer Lett. 323:77–87. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stern DF: ERBB3/HER3 and ERBB2/HER2 duet
in mammary development and breast cancer. J Mammary Gland Biol
Neoplasia. 13:215–223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao L and Vogt PK: Class I PI3K in
oncogenic cellular transformation. Oncogene. 27:5486–5496. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Grewe M, Gansauge F, Schmid RM, Adler G
and Seufferlein T: Regulation of cell growth and cyclin D1
expression by the constitutively active FRAP-p70s6K pathway in
human pancreatic cancer cells. Cancer Res. 59:3581–3587.
1999.PubMed/NCBI
|
|
37
|
Biechele TL, Kulikauskas RM, Toroni RA,
Lucero OM, Swift RD, James RG, Robin NC, Dawson DW, Moon RT and
Chien AJ: Wnt/β-catenin signaling and AXIN1 regulate apoptosis
triggered by inhibition of the mutant kinase BRAFV600E in human
melanoma. Sci Signal. 5:ra32012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arnold HK, Zhang X, Daniel CJ, Tibbitts D,
Escamilla-Powers J, Farrell A, Tokarz S, Morgan C and Sears RC: The
Axin1 scaffold protein promotes formation of a degradation complex
for c-Myc. EMBO J. 28:500–512. 2009. View Article : Google Scholar : PubMed/NCBI
|
